Why stopping GLP-1 drugs may undo weight loss and heart gains

Continuous GLP-1 use was associated with an 18% reduction in heart attack or stroke risk over three years; stopping for two years raised risk by 22% in a BMJ Medicine study of >330,000 VA patients. Discontinuation rates are high (36–81% within one year; a 2025 study found 65% of non-diabetics stopped within a year), driven largely by cost and limited insurance coverage (employer coverage for obesity GLP-1s ~49% in 2025). For investors, the results support the clinical case for long-term GLP-1 use (structural demand), but affordability and coverage gaps pose downside risk to uptake and revenue realization.

Analysis

The key economic lever from the recent clinical signal is that GLP‑1 therapies look to be chronic products in practice, not finite courses; that converts a one‑off prescribing event into an annuity only to the extent patients stay on therapy. Payers will therefore evaluate coverage through the lens of persistence-adjusted unit economics, forcing manufacturers into outcome‑based contracts, deeper cash discounts for uninsured patients, or adherence programs to protect realized revenue per patient over multiple years.

From a competitive standpoint, scale and cost of goods will determine winners. Companies with integrated manufacturing, long lead times to expand peptide capacity, and deeper rebate war chests will be able to defend share while compressing rivals’ margins; conversely, suppliers of peptide synthesis and fill/finish services are a second‑order beneficiary as demand shifts from episodic to sustained dosing. At the system level, repeated stop‑start treatment creates downstream demand for cardiometabolic care (statins, antihypertensives, hospital admissions) that partially offsets payer savings and may prompt tighter monitoring or guideline changes.

Catalysts to watch over the next 3–18 months are payer policy updates, new coverage mandates from large employers or CMS, public pricing concessions by manufacturers, and any regulatory guidance tying long‑term CV benefit to continuous exposure. Major reversals would come if randomized longer‑term data show durable cardioprotection after fixed‑duration treatment or if adherence programs materially raise persistence; both would re‑rate the durability of revenue and compress the case for outcomes pricing.

Key Decisions for Investors

• Long NVO via 9–15 month call spread (buy ITM call / sell higher OTM) to play durable demand and pricing power while capping premium — R/R: capture continued penetration upside if payers relent on chronic coverage; risk: rebates/price cuts and competition compress margins.
• Pair trade: long NVO / short LLY equal notional (12 months) — thesis: scale and manufacturing lead times favor semaglutide incumbency while tirzepatide faces slower commercial ramp and pricing pushback. Reward if persistence/coverage favors incumbent; tail risk if clinical differentiation decisively accelerates share shift.
• Buy selective CDMO exposure (peptide-focused contract manufacturers) on pullback (6–18 months) — small allocations to names with peptide fill/finish capability to capture secular increase in recurring dosing volumes. Upside if sustained use forces capacity expansion; downside if demand proves episodic and outsources consolidate.
• Event hedge: purchase short‑dated protection (puts) on mid/small cap obesity‑exposed names ahead of major payer coverage announcements (3 months) — protects portfolio against rapid de‑rating from negative reimbursement news that would compress near‑term revenue projections.